Role of nitric oxide in Salmonella typhimurium-mediated cancer cell killing.
BACKGROUND
Bacterial targeting of tumours is an important anti-cancer strategy. We previously showed that strain SL7838 of Salmonella typhimurium targets and kills cancer cells. Whether NO generation by the bacteria has a role in SL7838 lethality to cancer cells is explored. This bacterium has the mechanism for generating NO, but also for decomposing it.


METHODS
Mechanism underlying Salmonella typhimurium tumour therapy was investigated through in vitro and in vivo studies. NO measurements were conducted either by chemical assays (in vitro) or using Biosensors (in vivo). Cancer cells cytotoxic assay were done by using MTS. Bacterial cell survival and tumour burden were determined using molecular imaging techniques.


RESULTS
SL7838 generated nitric oxide (NO) in anaerobic cell suspensions, inside infected cancer cells in vitro and in implanted 4T1 tumours in live mice, the last, as measured using microsensors. Thus, under these conditions, the NO generating pathway is more active than the decomposition pathway. The latter was eliminated, in strain SL7842, by the deletion of hmp- and norV genes, making SL7842 more proficient at generating NO than SL7838. SL7842 killed cancer cells more effectively than SL7838 in vitro, and this was dependent on nitrate availability. This strain was also ca. 100% more effective in treating implanted 4T1 mouse tumours than SL7838.


CONCLUSIONS
NO generation capability is important in the killing of cancer cells by Salmonella strains.
Barak
Yoram
Y
Department of Microbiology and Immunology, Sherman Fairchild Science Building, Stanford University School of Medicine, 299 Campus Drive, Stanford, CA 94305, USA.
Schreiber
Frank
F
Thorne
Steve H
SH
Contag
Christopher H
CH
Debeer
Dirk
D
Matin
A
A
D000818:Animals; D001691:Biological Therapy / Q000379:methods*; D015374:Biosensing Techniques; D016923:Cell Death; D045744:Cell Line, Tumor; D002470:Cell Survival; D015964:Gene Expression Regulation, Bacterial; D006801:Humans; D006834:Hydrazines / Q000494:pharmacology; D051379:Mice; D008807:Mice, Inbred BALB C; D009369:Neoplasms / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D009569:Nitric Oxide / Q000378:metabolism*; D020030:Nitric Oxide Donors / Q000494:pharmacology; D012486:Salmonella typhimurium / Q000235:genetics / Q000378:metabolism*; D013997:Time Factors; D047368:Tumor Burden
D006834:Hydrazines; D020030:Nitric Oxide Donors; D009569:Nitric Oxide; C084012:1,1-diethyl-2-hydroxy-2-nitrosohydrazine
World J Gastroenterol. 2007 Dec 21;13(47):6379-84
18081227
Microbiol Mol Biol Rev. 1997 Dec;61(4):533-616
9409151
Mol Med Today. 2000 Apr;6(4):157-62
10740254
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6640-5
10829079
Bioessays. 2005 Dec;27(12):1228-38
16299735
Nat Biotechnol. 1999 Jan;17(1):37-41
9920266
Nat Rev Cancer. 2004 Jun;4(6):437-47
15170446
Cancer Res. 1999 Dec 1;59(23):5863-70
10606224
Anal Chem. 2008 Feb 15;80(4):1152-8
18197634
Methods Enzymol. 1994;233:240-50
8015461
Microbiology (Reading). 1999 Nov;145 ( Pt 11):3035-3045
10589711
Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15155-60
11724950
Nat Rev Cancer. 2006 Aug;6(8):583-92
16862189
Thorax. 2000 Dec;55(12):1046-51
11083891
Biochem Soc Trans. 2005 Aug;33(Pt 4):701-4
16042578
Cancer Res. 1997 Oct 15;57(20):4537-44
9377566
Mol Cancer Ther. 2009 Feb;8(2):333-41
19190118
Mol Cancer Ther. 2006 Jan;5(1):97-103
16432167
Mol Gen Genet. 1990 Aug;223(1):156-8
2259337
Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17207-12
16282376
Environ Microbiol. 2005 Sep;7(9):1392-404
16104862
Cancer Res. 2005 Jul 15;65(14):6097-104
16024610
Expert Opin Biol Ther. 2001 Mar;1(2):291-300
11727536